Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Versus Durvalumab in Patients With Locally Advanced, Unresectable, PD-L1-Selected Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Concurrent Chemoradiotherapy
Conditions
Interventions
Tislelizumab
Durvalumab
+3 more
Locations
35
United States
XCancer/Centeral Care Center
Bolivar, Missouri, United States
Southern Medical Day Care Centre
Wollongong, New South Wales, Australia
Townsville Hospital
Douglas, Queensland, Australia
Lyell McEwin Hospital
Elizabeth Vale, South Australia, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Cabrini Hospital
Malvern, Victoria, Australia
Start Date
June 17, 2021
Primary Completion Date
October 17, 2023
Completion Date
October 17, 2023
Last Updated
October 31, 2024
NCT05671510
NCT03340506
NCT06066138
NCT07485114
NCT05098132
NCT04977453
Lead Sponsor
BeiGene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions